• Patent 1: He has been the lead scientist and inventor of a novel and selective AT2R analogs presenting antitumor properties (patent WO 2013091883) with MRCT, LMB, Cambridge, UK. Our lab in 2014 was awarded a Development Gap Fund (DGF) from the Medical Research Council Technology in London, a pre-seed translational fund, which provides funding to conduct translational research.
  • Patent 2: A second patent is being currently filled with collaboration with the pharmaceutical company ELPEN, on the discovery of a novel tumor homing peptide selectively targeting glia.
  • Patent 3: A third patent has been filed towards the construction of the smallest online bioreactor for rapid biotransformation of natural products and ligand-protein interaction monitoring
  • Patent 4: A fourth patent is currently in preparation towards the development of a novel cheminformatics server for the rapid determination of natural products from complex plant extracts.
  • Patent 5: A fifth patent is currently under preparation with Imperial College, London, towards a new formulation of the glioblastoma drug temozolomide that allowed the enhancement of its aqueous solubility as also its stability.